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Abstract
Background and Aims: Following liver resection (LR) for HCC, the likelihood
of survival is dynamic, in that multiple recurrences and/or metastases are
possible, each having variable impacts on outcomes. We sought to evaluate
the natural progression, pattern, and timing of various disease states after
LR for HCC using multistate modeling and to create a practical calculator to
provide prognostic information for patients and clinicians.
Approach and Results: Adult patients undergoing LR for HCC between
January 2000 and December 2018 were retrospectively identified at a single center. Multistate analysis modeled post-LR tumor progression by describing transitions between distinct disease states. In this model, the states
included surgery, intrahepatic recurrence (first, second, third, fourth, fifth),
distant metastasis with or without intrahepatic recurrence, and death. Of the
486 patients included, 169 (34.8%) remained recurrence-free, 205 (42.2%)
developed intrahepatic recurrence, 80 (16.5%) developed distant metastasis,
and 32 (7%) died. For an average patient having undergone LR, there was
a 33.1% chance of remaining disease-free, a 31.0% chance of at least one
intrahepatic recurrence, a 16.3% chance of distant metastasis, and a 19.8%
chance of death within the first 60 months post-LR. The transition probability from surgery to first intrahepatic recurrence, without a subsequent state
transition, increased from 3% (3 months) to 17.4% (30 months) and 17.2% (60
months). Factors that could modify these probabilities included tumor size,
satellite lesions, and microvascular invasion. The online multistate model calculator can be found on https://multistatehcc.shinyapps.io/home/.
Conclusions: In contrast to standard single time-to-event estimates, multistate
modeling provides more realistic prognostication of outcomes after LR for HCC
by taking into account many postoperative disease states and transitions between

Abbreviations: IQR, interquartile range; LR, liver resection; MELD, Model for End-Stage Liver Disease; MWA, microwave ablation; RFA, radiofrequency
ablation; STROBE, Strengthening the Reporting of Observational Studies in Epidemiology; TACE, transarterial chemoembolization.
© 2022 American Association for the Study of Liver Diseases.
Hepatology. 2022;00:1–11.	
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MULTISTATE MODELING OF HCC RECURRENCE

them. Our multistate modeling calculator can provide meaningful data to guide
the management of patients undergoing postoperative surveillance and therapy.

I NTRO DUCTI O N
HCC represents a leading cause of cancer death worldwide.[1] Liver resection (LR) is reserved for patients with
preserved liver function in the absence of extrahepatic
disease.[2– 4] Although cure can be achieved with LR, up
to 70% of patients develop disease recurrence within
5 years of resection, with the majority occurring in the
liver.[5] If standardized treatment algorithms are applied, the median survival of all comers with recurrence
is approximately 21 months.[5]
Postsurgical oncologic outcomes are typically reported as solitary binary events, such as dead versus
alive or presence versus absence of disease. While
these estimates offer information to evaluate the impact
of patient, tumor, and treatment variables, they do not
consider disease progression for pathologies where
recurrence is not universally fatal. Because prognosis is contingent upon the disease state a patient is
in and the patient’s path to that state, these types of
assumptions may yield oversimplified estimates of outcomes. Prognostication that incorporates various disease states (e.g., first, second, third, fourth, and fifth
intrahepatic recurrences; both intrahepatic and distant
metastases; distant metastases alone) may offer more
realistic probabilities for patients in a specific disease
state after curative-intent treatment in efforts to guide
individualized treatment strategies. Though multistate
modeling has been used to model progression of liver
fibrosis due to hepatitis C after liver transplantation, it
has not previously been used to model disease progression in HCC.[6]
Given that the likelihood of disease and survival
post-LR for HCC is dynamic, we sought to evaluate the
natural progression, pattern, and timing of the various
disease states after LR for HCC using multistate modeling and to create a practical calculator in order to provide prognostic information for patients and clinicians.

M ATE R I A LS A N D M ETH O DS

American Association for the Study of Liver Diseases
guidelines.[7] Patients with preoperative tumor rupture,
prior HCC treatment (including LR, liver transplant, and
locoregional therapies such as radiofrequency ablation
[RFA], transarterial chemoembolization [TACE], and
microwave ablation [MWA]), missing pathology information, or fibrolamellar subtype on pathology were excluded. A Strengthening the Reporting of Observational
Studies in Epidemiology (STROBE)–compliant diagram
of patients included and excluded is shown in Figure 1.
This study complies with the STROBE statement for
retrospective studies.[8] This study was approved by our
institutional research ethics board (REB#16-5626), and
a waiver of informed consent was obtained.

Data collection
We recorded patient demographics, age, sex, etiology
of liver disease, preoperative degree of liver dysfunction (Model for End-stage Liver Disease [MELD] and
Child-
Pugh score), preoperative laboratory variables
(albumin, total bilirubin, international normalized ratio,
albumin-
bilirubin grade, and platelet count), alpha-
fetoprotein (categorized to reflect clinically relevant
categories <20, 20–99, 100–999, and >1000),[9] preoperative tumor characteristics, pathology findings, and
postoperative outcomes. Major hepatectomy was defined as complete resection of three or more liver segments according to the Brisbane 2000 terminology.[10]
Pathology characteristics included the size of the largest tumor, tumor number, presence of satellite lesions,
tumor differentiation, vascular invasion, surgical margin
positivity, Laennec stage of adjacent liver fibrosis, and
degree of liver steatosis. Tumor differentiation was defined according to the modified Edmondson criteria.[11]
Treatments for recurrence were defined as ablation
(including RFA, MWA, ethanol injection), TACE, LR,
non-LR (including lung resection), systemic therapy, radiation, liver transplantation, and palliative care.

Study population

Follow-up, survival, and recurrence

We retrospectively studied consecutive adults (≥18
years) who underwent LR for HCC between January
2000 and December 2018 at a single academic institution (Toronto General Hospital). Patients with LR after
2018 were excluded, to allow for enough follow-up time
to evaluate tumor recurrence after LR. At the time of
analysis, patient data were up to date as of May 28,
2020. The diagnosis of HCC was established per the

Postoperatively, patients underwent surveillance with
contrast-
enhanced CT of the chest and abdomen
or ultrasound every 3 months for the first 2 years.
Subsequently, surveillance proceeded in 6-month intervals up to 5 years. Additional imaging studies were
obtained in the case of a suspected recurrence and included contrast-enhanced CT, contrast-enhanced ultrasound, or MRI.[7] Additional information on recurrence
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STROBE flow diagram of study cohort

included the date of recurrence and the location of recurrence. The latter was categorized as intrahepatic if
the recurrence was confined to the liver and as extrahepatic if distant.

Outcome measures
The primary aim was to model disease progression
after curative-intent primary HCC LR (HCC recurrence
[intrahepatic or distant] and/or death).

Statistical analysis
Descriptive data were expressed as medians and interquartile ranges (IQR) for non-
normally distributed
variables. Normally distributed continuous variables
were expressed as means with SD. Categorical variables were expressed using numbers and percentages. To visualize and estimate the incidence of first,
second, third, fourth, and fifth intrahepatic recurrences,
a Kaplan-
Meier method with a clock-
reset approach
was applied. Patients without recurrence, distant metastasis, or death were censored. The demonstration
of this Kaplan-Meier method was to illustrate the process and serve as a bridge between the traditional
survival estimate method and the multistate modeling. To model post-
LR tumor progression, a time-
nonhomogeneous Markov multistate model was used
to describe transitions between several well-defined,
distinct states. In the selected model, the states included surgery, first intrahepatic recurrence, second
intrahepatic recurrence, third intrahepatic recurrence,

fourth intrahepatic recurrence, fifth intrahepatic recurrence, a separate state encompassing any intrahepatic
and distant metastasis or distant metastasis alone, and
death (absorbing state). Patients who did not progress
to another state remained in their most recent state,
regardless of treatment received (e.g., transplant). In
this progressive multistate model, transitions are only
allowed in the forward direction. Based on these transitions, a matrix was constructed and formed the basis
for estimating the transition intensity functions used to
estimate risk (transition probability) functions. These
include rates of events, distributions of “sojourns” or
times between events, the proportion of individuals in
a particular “state,” and transition probabilities between
states of a specific period. Moreover, fixed covariate effects were evaluated through adjustments by age, sex,
and post-LR pathology variables—these are reported
as HRs. In the msm package used for the multistate
modeling, individual-specific or time-dependent covariates were allowed to be fitted to transition intensities.[12]
For the calculation of transition probabilities on which
the likelihood depends, time-dependent covariates are
assumed to be piecewise-
constant. Models with intensities that change with time are referred to as time-
inhomogeneous.[12] In the models, a variable to model
the effect of a potentially curative therapy of recurrence
was included. This was defined as any locoregional
curative intent treatment (including ablation, LR, and
transplant listing). All other treatments (TACE, systemic
therapy, radiation therapy, nonliver surgery, and palliative care) were considered as not potentially curative therapy for recurrence. Moreover, we considered
that the effect of sex is likely to be the same between
states for higher-level recurrences. Consequently, we
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constrained the effects of sex for all types of recurrence
(i.e., transition from no recurrence to first intrahepatic
recurrence = first intrahepatic recurrence to second intrahepatic recurrence transition, etc.; transition from no
recurrence to distant recurrence = first intrahepatic recurrence to distant recurrence transition, etc.; transition
from no recurrence to death = first intrahepatic recurrence to death transition, etc.). Hypothesis testing was
performed using a log likelihood test comparing the sex
coefficient–constrained model and the nonconstrained
model. Given that the models were not statistically significantly different, the constrained model was selected
as the final model. Finally, all analyses were performed
using a complete-case analysis.
All two-sided p values < 0.05 were considered statistically significant. Statistical analyses were performed
using R, version 4.0.3 (http://www.R-
proje
ct.org/).
Multistate modeling was performed using the msm and
survival packages. An online interactive probability estimate calculator was developed using the R package
shiny to provide prognostic information for patients at
three time points—postsurgery, at first intrahepatic recurrence, and at second intrahepatic recurrence.

R ESULTS
Study population

MULTISTATE MODELING OF HCC RECURRENCE

TA B L E 1

Overall patient cohort
Overall (n = 486)

Age, median (IQR)

63 (55–71)

Missing, n (%)

2 (0.4%)

Gender, n (%)
Male
Missing, n (%)

386 (79.4%)
0 (0%)

Etiology, n (%)
No underlying liver disease

57 (11.7%)

HBV

234 (48.1%)

HCV

106 (21.8%)

EtOH

28 (5.8%)

NASH

22 (4.5%)

HBV and HCV coinfection

1 (0.2%)

Other

38 (7.8%)

Missing, n (%)

0 (0%)

BMI, median (IQR)

24.90 (22.00–28.00)

Missing, n (%)

85 (17.5%)

Ascites within 30 days prior to
surgery, n (%)
Yes
Missing, n (%)

1 (0.2%)
6 (1.2%)

Encephalopathy, n (%)
No encephalopathy

407 (99.5%)

Grade 1–2

2 (0.5%)

A total of 486 patients were included. The median follow-up was 41.8 (IQR, 19.1–84.2) months. The majority of patients were male (79.4%), with an underlying
disease etiology of HBV (48.1%). The median preoperative MELD score was 7.0 (IQR, 6.4–8.0) (Table 1).
The median preoperative tumor size was 5.0 cm (IQR,
3.5–7.9), and most tumors were solitary (Table 2).

Missing, n (%)

Postresection outcomes:
recurrence and death

Missing, n (%)

1 (0.2%)

LR completed laparoscopically, n (%)

83 (17.1%)

Missing, n (%)

0 (0%)

Major hepatectomy, n (%)

250 (51.4%)

Missing, n (%)

0 (0%)

Length of stay after surgery, median
(IQR)

7.00 (5.00– 9.00)

Missing, n (%)

26 (5.3%)

Of the 486 patients who underwent curative-
intent
liver resection, 169 patients remained recurrence-free
throughout the follow-up period, 205 developed an intrahepatic recurrence, 80 developed distant metastasis,
and 32 patients died without a diagnosis of any recurrence. Of the patients who developed a first intrahepatic
recurrence, 64 remained in the first intrahepatic recurrence state, 111 developed a second intrahepatic recurrence, 16 developed a distant recurrence, and 14 died.
A flow diagram of the state transitions and the number
of patients in each state is shown in Figure 2 and Table
S1. The various treatments for HCC recurrence in each
state are shown in Table 3. The proportion of patients
treated with ablation decreased with each subsequent
intrahepatic recurrence (first, 49.7%; second, 40.5%;
third, 35.0%; fourth, 28.6%; fifth, 23.8%). In contrast,

77 (15.8%)

HTN requiring medication, n (%)
Yes
Missing, n (%)

236 (49.2%)
6 (1.2%)

BCLC stage, n (%)
0

17 (3.5%)

A

425 (87.6%)

B

43 (8.9%)

Abbreviations: BCLC, Barcelona Clinic liver cancer; BMI, body mass index;
EtOH, ethyl alcohol, HBV, hepatitis B virus; HCV, hepatitis C virus; HTN,
hypertension; IQR, interquartile range; LR, liver resection; NASH, Non-
alcoholic steatohepatitis.

the proportion of patients who received TACE increased
from 14.1% after the first intrahepatic recurrence to approximately one third in subsequent intrahepatic recurrences (Table 3).
Using the clock-reset approach, the transition between
states of intrahepatic recurrences accelerated with a
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TA B L E 2

Laboratory and tumor characteristics

Preoperative AFP (ng/ml), median
(IQR)

Overall (n = 486)
Missing
Macrovascular invasion on pathology,
n (%)

17 (4–432)

Missing

Preoperative AFP (ng/ml), n (%)
Missing

62

0–20

218 (51.4%)

20– 99

60 (14.2%)

100–999

69 (16.3%)

>1000

77 (18.2%)

Microvascular invasion on pathology,
n (%)
Missing

2
70 (14.6%)
5
240 (50.0%)
6

Fibrosis, Laennec grade, median (IQR) 3.00 (2.00– 4.00)
Cirrhosis
Missing

315 (64.9%)
1

Preoperative MELD, median (IQR)

7.00 (6.43– 8.00)

Preoperative platelet count (100,000),
median (IQR)

193.00
(153.75–249.00)

Preoperative INR, median (IQR)

1.02 (0.97–1.07)

Missing

2

Preoperative total bilirubin (mg/dl),
median (IQR)

10.00 (8.00–14.00)

Multiple

117 (24.2%)

Preoperative albumin (g/dl), median
(IQR)

42.00 (39.00– 4 4.00)

Single

367 (75.8%)

Preoperative creatinine (μmol/L),
median (IQR)

77.00 (68.00– 9 0.00)

Preoperative Child-Pugh grade, n (%)
Missing

41

A5

410 (92.1%)

A6

29 (6.5%)

B7

6 (1.3%)

Preoperative ALBI, median (IQR)

Steatosis, median (IQR)

1.00 (0.00–1.00)

Tumor number on pathology, n (%)

Postoperative AFP (ng/ml), n (%)
Missing

98

0–20

302 (77.8%)

20– 99

30 (7.7%)

100–999

29 (7.5%)

>1000

27 (7.0%)

Abbreviations: AFP, alpha-fetoprotein; ALBI, albumin-bilirubin; INR,
international normalized ratio; IQR, interquartile range; MELD, model for
end-stage liver disease.

−2.86 (−3.05 to −2.63)

Preoperative ALBI grade, n (%)
Missing

42

1

344 (77.5%)

2

100 (22.5%)

Tumor size preoperatively (cm),
median (IQR)

5.00 (3.50–7.90)

Tumor number preoperatively, median
(IQR)

1.00 (1.00–1.00)

Missing

0 (0%)

Multiple

60 (12.3%)

Single

426 (87.7%)

Satellite lesions preoperatively, n (%)

5

(Continued)

Overall (n = 486)
Preoperative variables

|

26 (5.3%)

Pathology and postoperative variables
Satellite lesions on pathology, n (%)

59 (12.1%)

Tumor size on pathology (cm), median
(IQR)

5.20 (3.50– 8.20)

Histologic grade, n (%)
Missing

10

Well differentiated

21 (4.4%)

Moderate differentiation

351 (73.7%)

Poor differentiation

94 (19.7%)

Undifferentiated

1 (0.2%)

Not able to be assessed/nonviable

9 (1.9%)

Surgical margin positive, n (%)

17 (3.5%)

(Continues)

higher intrahepatic recurrence (Figure 3). The 1-year intrahepatic recurrence-
free probability was 76.2% after
the first intrahepatic recurrence, 58.2% after the second,
48.7% after the third, 39.9% after the fourth, and 54.6%
after the fifth. Similarly, transitions from each state to death
accelerated with each intrahepatic recurrence (Figure S1).
The maximum likelihood estimates of the mean sojourn
time (average period [months] of single stay in a state—i.e., temporary stay) for each nonabsorbing state are
shown in Table S2. There was a progressive shortening in
the estimates of the mean sojourn time (months) with the
exception of the fourth and fifth intrahepatic recurrences
(surgery 54.29, first intrahepatic recurrence 33.64, second intrahepatic recurrence 18.15, third intrahepatic recurrence 10.34, fourth intrahepatic recurrence 14.40, fifth
intrahepatic recurrence 69.17) (Table S2).
The probability of making a transition from the surgery state over time is shown in Figure 4. The probability of remaining in the surgery state decreased from
94.6% at 3 months to 57.5% at 30 months and 33.1% at
60 months. In contrast, the probability of transitioning
from the surgery state to a first intrahepatic recurrence
increased from 3.0% at 3 months to 17.5% at 30 months
and 17.3% at 60 months (Tables S3–S5). The 3-month,
30-month, and 60-month probabilities of transitioning
to a distant recurrence and death from initial surgery
were 1.3%, 10.3%, and 16.2% and 1.0%, 8.0%, and

6
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FIGURE 2

MULTISTATE MODELING OF HCC RECURRENCE

Number of patients in each state

19.8%, respectively (Tables S3–S5). In other words,
a typical patient in the first state “surgery,” disease-
free after curative-intent LR, has a 33.1% probability
of being disease-free, a 31.0% probability of having an
intrahepatic recurrence (first, second, third, or higher),
a 16.3% probability of having a distant recurrence (with
or without intrahepatic recurrence), and a 19.8% probability of death in the first 60 months after surgery.
The probability of making a transition from the first
intrahepatic recurrence over time is shown in Figure 5.
The probability of remaining in the first intrahepatic recurrence state decreased from 91.5% at 3 months to
41.0% at 30 months and 16.8% at 60 months. In contrast, the probability of transitioning from the first intrahepatic recurrence state to the second intrahepatic
recurrence progressed from 6.1% at 3 months to 20.1%
at 30 months and 12.1% at 60 months. The 3-month,
30-month, and 60-month probabilities of transitioning to
a distant recurrence or death from the first intrahepatic
recurrence were 1.0%, 12.1%, and 19.3% and 1.0%,
12.1%, and 29.7%, respectively. The probability of transition from a distant recurrence is depicted in Figure
S2. The probability of making a transition and reaching
each state from the surgery state (post–curative-intent
surgery) over the first 5 years depending on pathology
covariates (including multiple tumors, large tumors [≥5
cm], satellite lesions, and microvascular invasion) is
shown in Figure S3. The probability of making a transition and reaching each state from the first intrahepatic
recurrence state over the first 5 years depending on
receipt of curative-intent treatment for the first intrahepatic recurrence is shown in Figure S4.
Transition intensities from surgery and first intrahepatic recurrence with HRs for various covariates are
shown in Tables S6 and S7, respectively. Covariates
associated with an increased HR of surgery to first intrahepatic recurrence transition included the presence
of satellite lesion on pathology (HR, 2.64; 95% CI,
1.76–3.96) and the presence of microvascular invasion
(HR, 1.54; 95% CI, 1.11–2.13). In contrast, while tumor
number and presence of a satellite nodule were not associated with the transition from surgery to a distant

recurrence (HR, 0.50; 95% CI, 0.22–1.16; and HR, 1.07;
95% CI, 0.52–2.19, respectively), larger tumor size (reference, <5 cm; HR, 2.55; 95% CI, 1.40–4.64) and microvascular invasion on pathology (HR, 4.16; 95% CI,
2.29–7.56) were covariates associated with this type of
transition (Table S6).
The online interactive probability estimate calculator
was developed to provide prognostic information for patients and clinicians at three time points—postsurgery,
at first intrahepatic recurrence, and at second intrahepatic recurrence. Three models are provided: baseline,
preoperative (based on variables that are known before surgery, such as age and sex), and postoperative
variables (based on variables that are known postoperatively, such as tumor-specific variables; this calculator can be found at https://multistatehcc.shinyapps.io/
home/).

D I SCUSS I O N
This study presents an analysis of HCC recurrence
post-
LR using multistate modeling. Using this technique, a patient’s prognosis is estimated based upon
not only the disease state a patient is in but also the
progression to that state. As opposed to standard time-
to-
one-
event estimates, we found the postoperative
course after initial HCC treatment to be highly variable
and dependent on the timing and pattern of disease
recurrence and/or metastasis. By incorporating these
states in our model, we were able to calculate more
realistic outcome probabilities of transitioning to a particular disease state and, in turn, develop a calculator
that could be used to provide meaningful prognostic information for both patients and clinicians.
The development of HCC recurrence (intrahepatic
and distant) after curative-intent LR is high, with estimates of 60%–70% at 5 years in major Western centers.[5,13] In our series, the estimate for disease-free
survival at 5 years was 53.2% using a standard statistical binary time-to- one- event method (Kaplan- Meier).
While these estimates provide general insight into

   

22 (28.2)

2
0

2 (9.5)
3 (8.6)

0
0

6 (10.0)

6
Missing, n (%)

0

15 (7.5)
Palliative care, n (%)

7 (6.3)

24 (30.8)

2 (2.6)
2 (9.5)

3 (14.3)
3 (8.6)

0
0

5 (8.3)

3 (1.5)
Radiation, n (%)

1 (0.9)

10 (5.0)
Systemic therapy, n (%)

4 (3.6)

0
2 (9.5)
3 (8.6)
4 (6.7)
12 (6.0)
Liver transplantation
(including bridging), n (%)

13 (11.7)

1 (1.3)

15 (19.2)
0

0
0

0
0

0

0
Resection (non- LR), n (%)

0

14 (7.0)
LR, n (%)

2 (1.8)

3 (3.8)

1 (1.3)
6 (28.6)

5 (23.8)
10 (28.6)

11 (31.4)
21 (35.0)

21 (35.0)

28 (14.1)
TACE, n (%)

31 (27.9)

99 (49.7)
Ablation, n (%)

45 (40.5)

10 (12.8)
1 (4.8)
5 (14.3)
3 (5.0)
8 (7.2)
18 (9.0)

First intrahepatic
recurrence (n = 205)

None, n (%)

TA B L E 3

Treatment received after each recurrence

Second intrahepatic
recurrence (n = 111)

Third intrahepatic
recurrence (n = 60)

Fourth intrahepatic
recurrence (n = 35)

Fifth intrahepatic
recurrence (n = 21)

Distant or intrahepatic and
distant recurrence (n = 80)

HEPATOLOGY
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disease recurrence postoperatively, they do not incorporate factors such as time to recurrence and other disease states known to influence outcomes. For example,
an estimate of the expected probability of disease-free
survival from curative LR may not be directly applicable
to patients who have already developed their first recurrence. In this case, estimating subsequent oncologic
events such as a second recurrence, distant recurrence, or death is contingent upon the development of
the first recurrence. Within this context, multistate modeling provides meaningful prognostic estimates to individual patients, which is particularly useful in diseases
such as HCC, where recurrence is not universally fatal.
Multistate modeling allows for adjustment of covariates, such as patient and tumor characteristics, that
can offer more individualized estimates. For example,
a patient who is 67 years old at the time of LR with two
HCC tumors that are large with surrounding satellite
nodules and microvascular invasion will have a different probability of transition to a first intrahepatic recurrence or distant recurrence than another patient who is
60 years old with one small focus of HCC without satellite nodules or vascular invasion. The differential prognostic estimates are reflected in the distinct probability
shapes (Figures S3a–d and S4a,b). This provides an
opportunity to tailor prognostic estimates to individual
patients based on their clinicopathologic characteristics. By modeling disease progression after curative-
intent LR, our calculator allows one to evaluate specific
questions relevant to patient counseling and recurrent
HCC behavior, including the following: (1) What is the
probability of a first intrahepatic recurrence within 6
months after curative intent LR? (2) What is the probability of dying within 6 months after curative intent LR
(with or without a recurrence)? and (3) What is the probability of dying within 6 months after the development of
a distant recurrence? It thus offers dynamic insight into
disease progression, pattern, and timing of HCC recurrence after curative-intent LR. Furthermore, given the
changing landscape of systemic therapy for HCC and
the potential for neoadjuvant and adjuvant therapies in
these population, this model can better inform future
clinical trials design because it may offer a means to
improve the stratification of disease.[14] Incorporating
information about disease states and the speed of progression between them may offer additional insight into
optimal treatment selection strategies. For instance, a
slow tumor progression in an 80-year-old patient may
warrant a different management strategy from that for
a younger patient with a faster disease progression.
The concept of timing of disease progression and its
relevance has been evaluated in other cancers such
as colorectal liver metastases[15] and metastatic renal-
cell carcinoma.[16] Nonetheless, it remains to be fully
explored in HCC.
While survival is adversely impacted following
recurrence, numerous treatments, including repeat
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FIGURE 3

MULTISTATE MODELING OF HCC RECURRENCE

Kaplan-Meier estimates of time to intrahepatic recurrence in a clock-reset approach

resection, ablation, TACE, radiation, and liver transplantation, can offer cure and prolong patient survival.
As the landscape of treating both primary and recurrent HCC has grown increasingly complex, algorithms
have been applied to guide the management.[5,17]
Nonetheless, the pursuit of any treatment should be
based on an informed discussion between the patient and the clinician. To actively participate in such
decision-making, patients must understand the risks
and expected outcomes of any given procedure and
their prognosis at any given clinical state and time.
Traditional solitary time-
to-
event estimates, while
useful, do not offer such prognostic insight in complex
multidisease states, such as HCC recurrence, which
involves multiple transitions and treatments over time.
As such, they may skew a patient’s understanding of
the disease process and their prognosis. Using a multistate model and explaining the progression through
possible disease states may help a patient make a

more informed decision when considering different
treatment modalities and enhance the understanding
of the disease prognosis. Within this context, the patient counseling regarding prognosis will be different if
the patient has just undergone a curative-intent LR or
has just developed a second local recurrence following curative-intent LR. It is therefore critical to capture
prognostic estimates that are relevant for individual
patients because they differ based on recurrence
and the number of recurrences. An accurate representation of covariate adjustment and the impact of
treatment requires a large and heterogeneous patient
sample to minimize selection bias and the effect of institutional treatment idiosyncrasies. This is necessary
because prognostic estimates are not static and are
likely to change depending on receipt and response
to therapies. Consequently, the future direction of this
analysis is external validation and refinement using a
multi-institutional patient cohort.
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F I G U R E 4 Probability of making a transition and reaching each state from the surgery state (postcurative-intent surgery) over the
first 5 years. The y axis represents probability, and the x axis represents months from the beginning state (in this case surgery state
[postcurative-intent surgery]). Each state is depicted by a different color. For the surgery state, depicted in blue, at time 0, the probability
of being in that state is 1.0 (100%). Over time, the probability of remaining in this state diminishes. In contrast, the probability of having
moved to (and stayed in) the first intrahepatic recurrence state (depicted in light yellow) progressively increases over time (e.g., the
probability of being in the first intrahepatic recurrence state at time 0 is 0.0 [0%]). A similar interpretation can be applied to other states. For
example, the probability of moving to (and staying in) the second intrahepatic recurrence state is negligible until a sufficient probability of
the first intrahepatic recurrence transitions has occurred (as moving to a second local recurrence is contingent on having developed a first
intrahepatic recurrence)

Limitations
This is a single-
center retrospective nonrandomized
study, with the potential for selection bias. However, the

study population does represent one of the largest samples from a high-volume North American center. Given
the diminishing number of transitions with each tumor
progression transition, multiple covariate adjustments
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FIGURE 5

MULTISTATE MODELING OF HCC RECURRENCE

Probability of making a transition and reaching each state from the first intrahepatic recurrence state over the first 5 years

were limited. Further, because of the single-institution
design, we cannot distinguish between the impact of
institutional and provider-based practices (e.g., time to
treatment of recurrence or selection of treatment modality for a given recurrence) from HCC disease biology. A larger multi-
institutional cohort is planned to
validate these findings and improve these results’ external validity and generalizability.
In conclusion, multistate modeling of HCC recurrence can be used to account for the various disease

states a patient can exist in and transition between
after curative-intent LR. In contrast to standard single
time-to-event estimates, multistate modeling provides
a more realistic prognostication of outcomes after
curative-intent surgery for HCC by taking into account
a multitude of postoperative disease states and transitions between them. Our multistate modeling calculator
can provide meaningful data to guide the management
of patients undergoing postoperative surveillance and
therapy.
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